EFFICACY AND SAFETY OF SABATOLIMAB (MBG453) IN COMBINATION WITH
HYPOMETHYLATING AGENTS (HMAS) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
(AML) AND HIGH-RISK MYELODYSPLASTIC SYNDROME (HR-MDS): UPDATED RESULTS
FROM A PHASE IB STUDY
Andrew Brunner1, Jordi Esteve2, Kimmo Porkka3, Steve Knapper4, Norbert Vey5, Sebastian Scholl6, Guillermo
Garcia-Manero7, Martin Wermke8, Jeroen Janssen9, Elie Traer10, Sun Loo11, Rupa Narayan1, Natalia Tovar2, Mika
Kontro3, Oliver Ottmann4, Purushotham Naidu12, Sema Kurtulus13, Jessica Makofske13, Wei He13, Anisa
Mohammed12, Catherine A. Sabatos-Peyton13, Mikael L. Rinne13, Uma Borate10 and Andrew H. Wei14
(1)Massachusetts General Hospital, Boston, (2)Hospital Clínic, Barcelona, Spain, (3)Helsinki University Hospital
Comprehensive Cancer Center, Department of Hematology, Helsinki, Finland, (4)Department of Hematology,
Cardiff University, Cardiff, United Kingdom, (5)Institut Paoli-Calmettes, Marseille, France, (6)University Hospital
Jena, Jena, Germany, (7)MD Anderson Cancer Center, Houston, (8)University Hospital Dresden, Dresden,
Germany, (9)Amsterdam University Medical Centers, Ioc VU University Medical Center, Amsterdam, Netherlands,
(10)Oregon Health & Science University, Portland, (11)The Alfred Hospital, Melbourne, Australia, (12)Novartis
Pharmaceuticals Corporation, East Hanover, (13)Novartis Institutes for BioMedical Research, Cambridge, (14)The
Alfred Hospital and Monash University, Melbourne, Australia
`
SCIENTIFIC PROGRAMME
SESSION I
ETIOLOGY OF MDS
SESSION II
BIOLOGY OF MDS –
GENETIC ABNORMALITIES
SESSION III
BIOLOGY OF MDS:
STEM CELLS AND THE
MICROENVIRONMENT
SESSION IV
DIAGNOSTIC WORKUP
AND PROGNOSTIC
FACTORS IN MDS
SESSION V
SPECIFIC SUBTYPES
OF MDS, BASED ON
MORPHOLOGY AND
MOLECULAR BIOLOGY
SESSION VI
TREATMENT OF MDS
SESSION VII
CURRENT PROGRESS IN
THE TREATMENT OF MDS
SESSION VIII
FUTURE TREATMENTS
AND TREATMENT
STRATEGIES IN MDS
SESSION IX
LATE-BREAKING TALKS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
AS E-POSTERS
DISCLOSURES